Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Peking University First Hospital | OTHER |
Not provided
Not provided
Not provided
Radiation therapy (RT) is an effective treatment for patients with advanced-stage clear cell renal cell carcinoma (ccRCC). Current evidence has shown promising outcomes combining radiation therapy and standard systemic therapy in patients with metastatic/recurrent ccRCC. CAIX is a highly sensitive and specific biomarker expressed on ccRCC and in previous studies the investigators have shown excellent diagnostic efficacy of 68Ga-NY104, a CAIX-targeted PET tracer, in patients with metastatic ccRCC. In this study, the investigators aim to investigate the effect of 68Ga-NY104, and 18F-FDG PET/CT guided RT combining standard systemic therapy in patients with metastatic ccRCC.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| NY104 and FDG guided RT combining systemic therapy | Experimental | In this arm, patients will undergo baseline evaluation using both 68Ga-NY104 and 18F-FGD PET/CT. Metastatic lesions will be identified based on these two PET/CTs and all other imaging modalities available. The radiation field will be planned to cover as much metastasis as possible if not all. Systemic therapy will be delivered at the same time. The patients will be followed up for disease status. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 68Ga-NY104 PET/CT | Drug | 68Ga-NY104 PET/CT will be performed at baseline, 6 months, 12 months, and 24 months after radiation therapy if the tumor is under control. If CT or MRI shows any suspicious recurrence or metastasis, 68Ga-NY104 PET/CT can be performed at the decision of the urology oncologist or radiation oncologist. The scan begins 1 hour after intravenous injection of 68Ga-NY104. |
| Measure | Description | Time Frame |
|---|---|---|
| Progression free survival 2, PFS2 | Progression Free Survival 2 (PFS2) was defined as the time from the beginning of treatment to the emergence of new lesions or the progression of original lesions, when the lesions could not be fully covered by radiotherapy, and the drug regimen had to be changed. | the time from the start of RT to 4 years after treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Lesion uptake on 68Ga-NY104 PET/CT | From the start of 68Ga-NY104 PET/CT to 1 week after the 68Ga-NY104 PET/CT | |
| Lesion uptake on 18F-FDG PET/CT | From the start of 18F-FDG PET/CT to 1 week after the 18F-FDG PET/CT |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Xianshu Gao, MD | Contact | +86 01083575641 | gao7777@139.com | |
| Mingwei Ma, MD | Contact | +86 0108372408 | dr.mingweima@stu.pku.edu.cn |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Peking University First Hospital | Recruiting | Beijing | Beijing Municipality | 100034 | China |
all IPD that underlie results in a publication
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D002292 | Carcinoma, Renal Cell |
| ID | Term |
|---|---|
| D000230 | Adenocarcinoma |
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
Not provided
Not provided
| ID | Term |
|---|---|
| D011878 | Radiotherapy |
| ID | Term |
|---|---|
| D013812 | Therapeutics |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| 18F-FDG PET/CT | Drug | 18F-FDG PET/CT will be performed at baseline and 6 months after radiation therapy. The scan begins 1 hour after intravenous injection of 18F-FDG. |
|
| Radiation Therapy | Radiation | Radiation therapy will be delivered to cover as much metastasis as possible if not all. For new lesions after radiation plus systemic therapy, if the new lesions are considered suitable for RT, RT can be delivered again without changing systemic therapy. |
|
| Systemic therapy | Drug | Systemic therapy will be delivered to patients to control the tumor. Possible regimen includes targeted therapy alone, immunotherapy alone, and targeted therapy combined with immunotherapy. The treatment regimen will be decided according to the urology oncologist. |
|
| Number of positive lesions detected on 68Ga-NY104 PET/CT | From the start of 68Ga-NY104 PET/CT to 1 week after the 68Ga-NY104 PET/CT |
| Number of positive lesions detected on 18F-FDG PET/CT | From the start of 18F-FDG PET/CT to 1 week after the 18F-FDG PET/CT |
| Number of lesions detected combining all available imaging modalities | From the start of any imaging modality to 1 week after completion of all imaging modalities |
| Objective response rate | The percentage of patients with complete remission or partial remission of tumor after treatment. | the time from the start of RT to 4 years after treatment |
| Progression free survival 1, PFS1 | Progression Free Survival 1 (PFS1) was defined as the time from the beginning of treatment to the emergence of new lesions or the progression of original lesions. | the time from the start of RT to 4 years after treatment |
| Disease control rate | The percentage of patients with complete remission, partial remission, or stable disease after treatment. | the time from the start of RT to 4 years after treatment |
| Overall survival | the time from the start of RT to 4 years after treatment |
| Adverse event | The adverse event due to PET/CT and treatment will be recorded according to CTCAE 5.0. | the time from the start of RT to 4 years after treatment |
| D009369 | Neoplasms |
| D007680 | Kidney Neoplasms |
| D014571 | Urologic Neoplasms |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052801 | Male Urogenital Diseases |